Latest News and Insights

Articles & Interviews

Business Insider

Press Releases

2026

Psilera Commends Landmark Executive Order Prioritizing Psychedelic Therapies

Psilera Commends Landmark Executive Order Prioritizing Psychedelic Therapies

Distinguished Neuroscience Expert Magali Haas, MD/PhD, Joins Psilera as Chief Medical Officer

Distinguished Neuroscience Expert Magali Haas, MD/PhD, Joins Psilera as Chief Medical Officer

2025

Psilera Inc. Secures National Institutes of Health Grant for AUD Research

Psilera Inc. Secures National Institutes of Health Grant for AUD Research

Healthcare Industry Veteran Scott Rairigh Joins Psilera to Lead Corporate Development

Healthcare Industry Veteran Scott Rairigh Joins Psilera to Lead Corporate Development

Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal Dementia

Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal Dementia

Psilera Inc. & atai Life Sciences Announce Licensing Agreement for DMT Patent Portfolio

Psilera Inc. & atai Life Sciences Announce Licensing Agreement for DMT Patent Portfolio

Biotechnology Company Psilera Convenes Prominent Industry Leaders & Patient Advocates for First FTD Research Summit

Biotechnology Company Psilera Convenes Prominent Industry Leaders & Patient Advocates for First FTD Research Summit

2024

USF Research Foundation Proudly Endorses and Invests In Psilera's FTD Research

USF Research Foundation Proudly Endorses and Invests In Psilera's FTD Research

Psilera Recieves Positive Preclinical In Vivo Data for FTD Candidate PSIL-006

Psilera Recieves Positive Preclinical In Vivo Data for FTD Candidate PSIL-006

Dr. Magali Haas, M.D., Ph.D. Joins Psilera as an Independent Board Member

Dr. Magali Haas, M.D., Ph.D. Joins Psilera as an Independent Board Member

Psilera Announces Lead Indication for PSIL-006: Behavioral Variant Frontotemporal Dementia (bvFTD)

Psilera Announces Lead Indication for PSIL-006: Behavioral Variant Frontotemporal Dementia (bvFTD)

2023

Psilera: Tampa Bay HealthTech Company of the Year and a Finalists for Company to Watch by GrowFL

Psilera: Tampa Bay HealthTech Company of the Year and a Finalists for Company to Watch by GrowFL

Psilera Receives Allowance on Flagship Patent Securing Novel Compound Library

Psilera Receives Allowance on Flagship Patent Securing Novel Compound Library

Psilera Unveils Psilocybin Derivative PSIL-006 As Lead Clinical Candidate

Psilera Unveils Psilocybin Derivative PSIL-006 As Lead Clinical Candidate

Non-Hallucinogenic Drug Candidates for First-in-Human Studies

Non-Hallucinogenic Drug Candidates for First-in-Human Studies

Psilera Co-Founders' Summer Conference Announcement

Psilera Co-Founders' Summer Conference Announcement

Psilera Presenting on International Stage at Biotech Showcase

Psilera Presenting on International Stage at Biotech Showcase

2022

First Patent Allowance for Transdermal Patch Formulations

First Patent Allowance for Transdermal Patch Formulations

2022 Wall Street Journal Health Forum and American Chemical Society Meeting

2022 Wall Street Journal Health Forum and American Chemical Society Meeting

USF and Morsani College of Medicine Funding Match for NCE's

USF and Morsani College of Medicine Funding Match for NCE's